To determine whether intensive combinations of synthetic disease modifying drugs (cDMARDS) achieve similar clinical benefits more cheaply than high-cost biologics such as tumour necrosis factor inhibitors (TNFis) in patients with active rheumatoid arthritis (RA) who have failed to respond to methotrexate and another DMARD.
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(previously demonstrated as likely to be cost-effective compared with DMARD monotherapy), [6] and biologic drugs like Tumour Necrosis Factor inhibitors (TNFis). Both approaches are clinically effective. While biologics show promise of cost-effectiveness as part of a treatment escalation approach,[7] they are nevertheless substantially more expensive and carry ongoing cost-effectiveness[8] and affordability concerns; methodological nuances also add to uncertainty over their cost-effectiveness. [8] In the TACIT trial, we compared clinical and economic outcomes of two intensive treatment strategies in patients with active RA who have failed to respond to methotrexate and another DMARD. One strategy was based on initially using combinations of conventional DMARDs (cDMARDs), using biologics only if patients failed to respond after 6 months. The other strategy was based on starting biologic therapy with tumour necrosis factor inhibitors (TNFis). Clinical outcomes showed starting with combinations of cDMARDs gave non-inferior clinical outcomes to starting with TNFis 9 . We now report the associated pre-planned economic evaluation.
MATERIALS AND METHODS

Design and Intervention
The TACIT trial was an open-label, 12-month, pragmatic, randomised, multicentre, two-arm, non-inferiority trial comparing two treatment strategies for RA patients -one starting with cDMARDS, the other with TNFis. 
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This article is protected by copyright. All rights reserved. trial (MREC Reference 07/Q0505/57) and participants provided informed consent. We recruited from 24 rheumatology clinics in England and Wales. We included men and women aged over 18 with disease durations over 12 months who met the 1987 criteria for classification of rheumatoid arthritis and National Institute for Health and Care Excellence (NICE) criteria for starting biologics in England and Wales.
[10] (Subsequent to our trial, NICE has recommended that biologics are used only if disease is severe and has not responded to intensive therapy with a combination of cDMARDs).
[11] We excluded those unable or unwilling to give informed consent, had not had successful results with or had contraindications to all combinations of disease modifying drugs (including possible pregnancy), had contraindications to TNFis, had serious inter-current illness, or were taking high dose corticosteroids (>10 mg prednisolone). Safety monitoring followed national guidance. Before randomisation all patients had received two disease modifying drugs; 62 had received three; 77 were taking combinations of two or more disease modifying drugs; and 24 were taking prednisone (mean dose 4 mg/day; range 1-7 mg). One hundred and sixty-two patients were receiving methotrexate at baseline (132 oral, 30 subcutaneous); the average dose was 18mg/week (range 5-25mg). Clinical characteristics of the sample, including use of medications, are reported in related publications [9, 12] .
The sample size was based on testing the null hypothesis of a difference of >0.22 (minimal clinically important change) on the Health Assessment Questionnaire between the two treatments. With a (one sided) testing level of 5%, we needed a sample size of 176 to achieve 90% power. We recruited 214 patients to allow for non-receipt of treatment or drop-outs. After screening for eligibility, consenting patients were randomised in blocks of
This article is protected by copyright. All rights reserved. four with allocation stratified by region. MedSciNet generated the allocation sequence; trial staff had no prior knowledge of the allocation sequence.
Patients allocated to the TNFi arm were given a particular TNFi depending on patient preference and local circumstances. Methotrexate was also given to patients on TNFis to maximise efficacy and reduce formation of antichimeric antibodies where necessary.
Patients intolerant to methotrexate took another DMARD. TNFi patients had their TNFi stopped and another started for 3 reasons: poor response (Disease Activity Score reduction <1.2) at 3 or 6 months; adverse events from medication; or patient choice. Patients who failed two TNFis, and were not able to start a third, were offered a cDMARD.
Patients allocated to the cDMARDs arm were given cDMARDs with proven efficacy over DMARD monotherapy. These included: triple therapy with methotrexate (methotrexatesulfasalazine-hydroxychloroquine); other methotrexate combinations (methotrexateciclosporin, methotrexate-leflunomide and methotrexate-gold); and a sulfasalazine combination (sulfasalazine-leflunomide). Additional monthly steroids (intramuscular Depo-Medrone (120 mg stat) or equivalent) were used if needed. cDMARDS were stopped for the same three reasons stated above for TNFis but poor response was judged at 6 months only.
Patients with poor response at 6 months were offered TNFis.
Resource use data
Trial medication use (name, dose, frequency and duration of use) was recorded prospectively on trial proformas by clinical and research staff over the entire study period.
Other individual-level economic data were captured by self-report using an adapted Client Service Receipt Inventory (CSRI; [13] see Hurley et al. [14] and Patel et al. [15] for similar applications), by interviewer-completed survey at baseline, and 6 and 12 months post randomisation, covering the previous 3-months. This covered socio-demographic data; use of (all-cause) community and secondary-based health and social care services and other medications; lost pay from illness-related time off work; receipt of social security benefits.
Costs
Individual-level resource-use data, including trial medications, were multiplied by appropriate unit costs (supplementary appendices 1 and 2) to calculate a cost per participant. Using a detailed approach, medication unit costs were converted into cost per milligram (mg) based on the most cost-efficient pack size, choosing maintenance prices over initial treatment prices and generic prices over branded ones to obtain conservative estimates (supplementary appendix 2). Total costs were then computed at baseline, 6 months and 12 months from three perspectives: health and social care perspective; societal, additionally including participant lost pay due to work absence; and a second societal, which further added social security benefits.
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Trial medication costs were available for the full 0-6 and 7-12 month periods; all other costs represented data collection periods of 4-6 months and 10-12 months inclusive, so were doubled to represent 6-month periods. All costs are reported in English pounds sterling at 2010/11 prices and can be converted to United States dollars ($) or Euros using the rates £1 = 1.42 or £1 = 1.28 respectively (based on 2011 purchasing power parities which equalise the purchasing power of the currencies [16] ). Discounting was unnecessary.
Outcomes
Cost-effectiveness analyses were based on the trial's primary outcome measure, the Health Assessment Questionnaire (HAQ), [17] accounting for lower scores indicating better outcome. Cost-utility analyses were based on quality-adjusted life years (QALYs), estimated by applying appropriate general population utility weights (Brazier et al. [18] ; Dolan et al. [19] to individual health statement measurements using both the Short-Form 36 (SF-36 [20] ) and the EuroQoL 5-Dimension measure (EQ-5D-3L [21] administered at baseline, 6 and 12 months. QALY gains between baseline and 6 months, and between 6 months and 12 months were then calculated as the total area under the curve.
Analyses
Costs and outcomes were compared at 6 and 12 months and are presented as means and standard deviations. Mean differences between trial arms and 95% confidence intervals (CIs) were obtained using non-parametric bootstrap regressions (1000 repetitions). For cost comparisons, we included covariates for baseline cost from the same cost perspective,
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baseline HAQ score, duration of illness, age, sex, region (a stratification factor in the randomisation process) and ethnicity. Outcome comparisons included covariates for baseline values of the same outcome plus baseline HAQ score, duration of illness, age, sex, region and ethnicity.
An electronic data capture system (MedSciNet AB, Stockholm, Sweden; http://medscinet.com) was programmed to disallow individual-item non-response on the service use section of the CSRI. For non-trial medication and other societal impacts, we imputed missing values as necessary (supplementary appendix 3).
We used available cases for each analysis. To explore the potential impact of excluding nonresponders we examined socio-demographic and clinical characteristics of responders versus the full sample and, in a sensitivity analysis, imputed missing 6-and 12-month total costs and outcomes using the multiple imputation command in Stata version 11.2. [22] Missing costs were imputed based on variables expected to predict total follow-up costs: baseline HAQ score, duration of illness, age, sex, region, ethnicity, trial arm and equivalent baseline cost (and equivalent cost at 6 months for 12-month imputations). Imputations of follow-up HAQ scores were based on baseline HAQ score, duration of illness, age, sex, region, ethnicity and trial arm (and HAQ score at 6 months for 12-month imputations).
Imputations of missing QALYs were based on baseline HAQ score, duration of illness, age, sex, region, ethnicity, trial arm and equivalent baseline utility score (and utility score at 6
This article is protected by copyright. All rights reserved. months for 12-month imputations). Resulting full sample cost and outcome data were analysed as per the main analyses.
Cost-effectiveness and cost-utility analyses
Accounting for the three cost perspectives and three outcomes, there were nine possible cost-outcome combinations to consider in the economic evaluation. Incremental costeffectiveness ratios (ICERs) were calculated only for combinations showing both significantly higher costs and better outcomes in either trial arm.
Uncertainty around cost-effectiveness/cost-utility from a health and social care perspective was explored using cost-effectiveness acceptability curves (CEACs) based on the net-benefit approach [23] to present the probability that the cDMARDS arm is cost-effective compared with the TNFis arm for a range of values (from £0 and £50,000) that a decision-maker would be willing to pay for an additional QALY or an additional point improvement in HAQ score.
Data were analysed using Stata version 11.2. [22] Trial registration
ISRCTN (International Standard Registered Clinical/soCial sTudy Number) 37438295
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RESULTS
Response rates
Two-hundred and five participants were recruited into the study: 101 into the TNFis arm and 104 into the cDMARDs arm. Details of trial medications are reported in related publications [9, 12] . Response rates to CSRI and outcome questionnaires and completion of trial medication data were 90% or above for all components at baseline and 6 and 12 months and across both trial arms. 191 (93%) participants had both cost and outcome data at 6 month follow-up and 186 to 188 (91 to 92%) had both cost and outcome data at 12 month follow-up. There were no notable differences in characteristics between the subsamples included in the available case analyses and the full sample (Table 1) .
Resource use
Resource use (not tested statistically) was broadly comparable between groups ( Table 2) .
General practitioner (GP) surgery visits, practice nurse surgery visits, repeat prescription requests and hospital outpatient appointments were common in both groups at all-time points, with other service use being relatively rare. The number of participants using nontrial concomitant medications was also similar in both groups at all-time points.
Costs
Costs for both groups were equivalent at baseline ( Table 3 ). Costs of social security benefits and lost income are small relative to health and social care costs. At 6 and 12 month follow-
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up, average values for cost categories remained equivalent between groups except for cost of trial medications, which was significantly lower in the cDMARDs arm (6-month adjusted mean difference −£3637, 95% CI −£3838 to −£3420; 12-month adjusted mean difference −£1894, 95% CI −£2320 to −£1427). The additional trial medication cost in the TNFis group overshadowed all other cost categories in that arm. The increase in trial medication costs between 6 and 12 months in the cDMARDs arm was due to a significant proportion of this group (n=46; 44%) switching to the more expensive TNFis at 6 months because of nonresponse to cDMARDs by 6 months. Switching in the reverse direction was uncommon (a total of four participants), so trial medication costs in the TNFis arm did not fall a great deal between 6 and 12 months.
The cDMARDs arm had significantly lower total costs from all perspectives at both followups. The difference is greater at 6 months than at 12 months because of the greater trial medication cost differential before switching taking place. Costs from both societal perspectives are similar to those from a health and social care perspective because of the dominance of trial medication costs.
Outcomes
At baseline, the cDMARDs arm had an advantage on utility scores estimated from the SF-36 but this did not carry through as an advantage in (baseline-adjusted) utility scores at either of the follow-ups or in the resulting QALY estimates (Table 4 ). The cDMARDs arm did,
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however, show advantages in terms of the HAQ and EQ-5D-3L based utility scores at 12 months, although the latter did not translate into QALY advantages.
Cost-effectiveness and cost-utility
Based on the HAQ, the cDMARDs arm dominated with better outcomes and lower costs at 12 months from all three perspectives. All other cost-outcome combinations similarly suggested that the cDMARDs strategy was preferable given equivalent outcomes were achieved at a significantly lower cost. CEACs showed high probabilities of cost-effectiveness for all examined cost-outcome combinations (Figure 1 ). Probabilities of cost-effectiveness at 6 months based on the HAQ were noticeably reduced after reaching thresholds greater than £10,000 per point improvement, but were consistently high at 12 months. Sensitivity analyses based on imputed missing data produced the same conclusions.
DISCUSSION
Key Findings
We show that, for patients with active RA who have failed to respond to methotrexate and another DMARD, starting treatment with cDMARDs produces similar HAQ and QALY outcomes at 6 months compared to starting treatment with TNFis, and is significantly cheaper (from all cost perspectives) largely due to the lower costs of cDMARD medications compared with TNFis. By 12 months, the cDMARD strategy has the advantage of statistically
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This article is protected by copyright. All rights reserved. significant better HAQ outcomes (−0.16, 95% CI −0.32 to −0.01) although the cost difference is smaller due to the large proportion (44%) of people switching from cDMARDs to TNFis.
The HAQ improvement is not clinically significant, so the clinically relevant conclusion is that the cDMARDs strategy provides non-inferior clinical outcomes to the TNFis strategy, but at significantly lower cost to the health and social care system. Adverse events are fully described elsewhere [9] but it is worth noting that serious adverse events and withdrawals because of toxicity were equally common with cDMARDs and TNFis. The total number of adverse events (ranging serious to minor) was though higher with cDMARDs, mainly due to 88 more adverse events related to the digestive system (148 vs. 60) and 20 more adverse events related to the nervous system (61 vs. 41).
Strengths and Limitations
This was a comprehensive and prospective economic evaluation, embedded within a robustly designed and implemented clinical trial with high follow-up rates. Other trials of cDMARDs have lacked such broad perspectives (e.g. Wailoo et al. [24] ). The multi-centre design and broad cost perspective necessitated some self-report, risking recall bias; we mitigated such risk by restricting recall periods to 3 months but this then necessitated data extrapolation to generate data for a 6-month period, which may not accurately reflect any variations in service use and other economic impacts across the measured and nonmeasured periods. Nevertheless, such biases are likely to be equivalent between arms and minimal given our finding that trial medication costs dominated total costs -these more influential medication data were available for the entire follow-up and were recorded prospectively by clinicians and the research team. Finally, we were unable to include
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informal care costs and only report one-year outcomes as longer-term modelling was beyond the scope of this study.
Comparison with other studies
There is now extensive evidence that intensive treatment strategies involving conventional The BeSt trial demonstrated that biologics might be cost-effective when accounting for lost productivity.
[28] The DRESS trial concluded that optimising TNFi dosing -to titrate to lowest dose -offers substantial cost savings without clinically significant QALY detriments. [31] 
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